Our aims were to determine the extent of coverage by designated palliative care services of the population of terminally ill cancer patients in South Australia, and to identify the types of patients who receive these services and the types who do not. All designated hospice and palliative care services in South Australia notified to the State Cancer Registry the identifying details of all their patients who died in 1999. This information was cross-referenced with the data for all cancer deaths (n=3086) recorded on the registry for 1999. We found that the level of coverage by designated palliative services of patients who died with cancer in 1999 was 68.2%. This methodology was previously used to show that the level of coverage had increased from 55.8% for cancer deaths in 1990 to 63.1% for those in 1993. Patients who died at home had the largest coverage by palliative services (74.7%), whereas patients who died in nursing homes had the lowest coverage (48.4%). Patients who did not receive care from these palliative services tended to be 80 years of age or older at death, country residents, those with a survival time from diagnosis of three months or less, and those diagnosed with a prostate, breast, or haematological malignancy. Gender, socioeconomic status of residential area, and race were not related to coverage by a designated palliative service, whereas migrants to Australia from the UK, Ireland, and Southern Europe were relatively high users of these services. We conclude that the high level of palliative care coverage observed in this study reflects widespread support for the establishment of designated services. When planning future care, special consideration should be given to the types of patients who most miss out on these services.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1191/0269216302pm571oa | DOI Listing |
Gan To Kagaku Ryoho
December 2024
Dept. of Palliative and Supportive Care, Institute of Medicine, University of Tsukuba.
Advance care planning(ACP)was officially incorporated into Japan's healthcare system in 2018 with the revision of the "Guidelines for the Decision-Making Process in End-of-Life Care"by the Ministry of Health, Labor and Welfare. This revision mandated that the government designated cancer hospitals and comprehensive community care wards establish systems for implementing ACP. Consequently, the implementation and promotion of ACP have become significant issues in the healthcare field.
View Article and Find Full Text PDFContemp Clin Trials
December 2024
Northwestern University Feinberg School of Medicine, Department of Medical Social Sciences, USA.
Adolescent and young adult cancer survivors (AYAs) experience clinically significant distress and have limited access to supportive care services. Interventions to enhance psychological well-being have improved positive affect and reduced depression in clinical and healthy populations and have not been routinely tested in AYA survivors. We are optimizing a web-based positive skills intervention for AYA cancer survivors called Enhancing Management of Psychological Outcomes With Emotion Regulation (EMPOWER) by: (1) determining which intervention components have the strongest effects on well-being and (2) identifying demographic and individual difference variables that mediate and moderate EMPOWER's efficacy.
View Article and Find Full Text PDFJCO Oncol Pract
December 2024
Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY.
Purpose: Financial toxicity (FT) is increasingly recognized as a major issue in cancer care. We evaluated the prevalence and risk factors for FT in patients with pancreatic ductal adenocarcinoma (PDAC) and FT associations with treatment adherence and quality of life (QOL).
Methods: A screening questionnaire based on the Comprehensive Score for Financial Toxicity (COST) was implemented at our National Cancer Institute-designated comprehensive cancer center.
J Grad Med Educ
December 2024
is Emeritus Professor of Pediatrics, Department of Pediatrics, Larner College of Medicine, University of Vermont, Burlington, Vermont, USA, and Pediatrics RC Public Member, ACGME, Chicago, Illinois, USA.
EBioMedicine
December 2024
Department of Human Oncology, UW School of Medicine and Public Health, Madison, WI, USA.
Background: Re-irradiation of recurrent head and neck cancer (HNC) is often limited by tumour adherence to critical structures and/or radiation tolerance of critical normal tissues. Iopofosine I 131 (CLR 131) is a targeted small molecular phospholipid ether (PLE) drug conjugate that delivers iodine-131 selectively to tumour cells. We conducted a phase 1, single-centre, open-label study to determine whether CLR 131 given with reduced dose of external beam radiation therapy (EBRT) would be tolerable and feasible.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!